🔎 Trials Near Me

Pradžia › Kiaušidžių vėžys › Ohio

Kiaušidžių vėžys klinikiniai tyrimai Ohio

70 tyrimai dėl Kiaušidžių vėžys ieško dalyvių vietose Ohio.

Miestai Ohio

Oficialus tyrimo tekstas (anglų kalba)

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

  • OhioHealth O'Bleness Hospital, Athens
  • UH Seidman Cancer Center at UH Avon Health Center, Avon
  • UHHS-Chagrin Highlands Medical Center, Beachwood
  • ir dar 39
Renkami dalyviai2 fazė
Visi amžiai · Visoms lytims · Atnaujinta 2026-10-02 · NCT05564377

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  • The Cleveland Clinic Taussig Cancer Center, Cleveland
Renkami dalyviai1/2 fazė
Amžius 12 ir vyresni · Visoms lytims · Atnaujinta 2026-10-02 · NCT04585750

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

  • University Hospitals Cleveland Medical Center, Cleveland
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-02 · NCT06465069

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

  • Cleveland Clinic - Oncology Department, Cleveland
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-02 · NCT06760819

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

  • University of Cincinnati Medical Center. /ID# 278925, Cincinnati
  • University Hospitals Cleveland Medical Center /ID# 279601, Cleveland
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Moterims · Atnaujinta 2026-10-01 · NCT07024784

Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer

  • Research Site, Cleveland
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Moterims · Atnaujinta 2026-10-01 · NCT07851025

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

  • Site 0147 - Trihealth Cancer Institute - Harold and Eugen, Cincinnati
  • Site 0243 - Mark H Zangmeister Cancer Center, Columbus
  • Site 0214-Ohio State University Comprehensive Cancer Center, Hilliard
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Moterims · Atnaujinta 2026-09-29 · NCT05128825

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

  • Metrohealth Medical Center - Cleveland /ID# 276664, Cleveland
  • Cleveland Clinic - Cleveland /ID# 276133, Cleveland
  • Cleveland Clinic - Cleveland /ID# 278273, Cleveland
  • ir dar 3
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Moterims · Atnaujinta 2026-09-29 · NCT06890338

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

  • Cleveland Clinic, Cleveland
Renkami dalyviaiStebimasis tyrimas
Amžius 18 ir vyresni · Moterims · Atnaujinta 2026-09-29 · NCT05051722

Study of AVZO-021 in Patients With Advanced Solid Tumors

  • Avenzo Therapeutics Recruiting Site, Cleveland
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-28 · NCT05867251

DESTINY-PANTUMOUR04

  • Research Site, Canton
  • Research Site, Maumee
Renkami dalyviaiStebimasis tyrimas
Amžius nuo 18 iki 130 · Visoms lytims · Atnaujinta 2026-09-25 · NCT07124000

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

  • The Ohio State University Comprehensive Cancer Center, Columbus
Renkami dalyviaiStebimasis tyrimas
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-25 · NCT04981119

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

  • The Ohio State University Wexner Medical Center, Columbus
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Moterims · Atnaujinta 2026-09-25 · NCT03564340

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

  • The Ohio State University Wexner Medical Center, Columbus
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Moterims · Atnaujinta 2026-09-24 · NCT04590326

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

  • Research Site, Cincinnati
  • Research Site, Columbus
Renkami dalyviai2 fazė
Amžius nuo 18 iki 130 · Visoms lytims · Atnaujinta 2026-09-23 · NCT05489211

A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

  • Jamescare Gynecologic Oncology At Mill Run /ID# 277951, Hilliard
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Moterims · Atnaujinta 2026-09-22 · NCT07059845

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

  • Miami Valley Hospital South, Centerville
  • University of Cincinnati Medical Center, Cincinnati
  • Oncology Hematology Care Inc, Cincinnati
  • ir dar 7
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-22 · NCT07213804

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

  • UH Cleveland Medical Center, Cleveland
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-17 · NCT07109726

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

  • University of Cincinnati Medical Center ( Site 0042), Cincinnati
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Moterims · Atnaujinta 2026-09-17 · NCT07318558

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  • Oncology Hematology Care, Inc, Cincinnati
  • The Mark H Zangmeister Cancer Center Ohio, Columbus
  • The Ohio State University Wexner Medical Center Division of Gynecologic Oncology, Hilliard
Renkami dalyviai2 fazė
Amžius nuo 18 iki 99 · Moterims · Atnaujinta 2026-09-15 · NCT07023627

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  • Cleveland Clinic Foundation, Cleveland
  • Ohio Health Research Institute, Columbus
  • Miami Valley Hospital South, Dayton
  • ir dar 1
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Moterims · Atnaujinta 2026-09-15 · NCT07214779

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

  • Christ Hospital, Cincinnati
  • Ohio State University, Columbus
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-14 · NCT06303505

Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial

  • Cleveland Clinic, Cleveland
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Moterims · Atnaujinta 2026-09-14 · NCT04575935

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

  • The Ohio State University Comprehensive Cancer Center, Hilliard
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Moterims · Atnaujinta 2026-09-14 · NCT06787612

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

  • Cleveland Clinic, Cleveland
  • Toledo Clinic Cancer Center, Toledo
Renkami dalyviaiStebimasis tyrimas
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-14 · NCT05059444

Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

  • Miami Valley Hospital South, Centerville
  • Zangmeister Cancer Center, Columbus
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Moterims · Atnaujinta 2026-09-09 · NCT07225270

A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

  • The Ohio State University (OSU) Wexner Medical Center, Columbus
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-04 · NCT06400472

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

  • University of Cincinnati Medical Center ( Site 0090), Cincinnati
  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0054), Columbus
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Moterims · Atnaujinta 2026-09-03 · NCT06824467

The Vanguard Study: Testing a New Way to Screen for Cancer

  • Louis Stokes Cleveland VA Medical Center, Cleveland
Renkami dalyviaiLaukiami sveiki savanoriai
Amžius nuo 45 iki 75 · Visoms lytims · Atnaujinta 2026-09-02 · NCT06995898

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

  • Cleveland Clinic, Cleveland
  • OhioHealth Research Institute, Columbus
  • Kettering Health, Kettering
  • ir dar 1
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Moterims · Atnaujinta 2026-08-26 · NCT05281471

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

  • The Ohio State University, Columbus
Renkami dalyviai1 fazė
Amžius 15 ir vyresni · Visoms lytims · Atnaujinta 2026-08-25 · NCT06276491

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

  • Cincinnati Children's Hospital Medical Center, Cincinnati
Renkami dalyviai1/2 fazė
12 Months – 30 Years · Visoms lytims · Atnaujinta 2026-08-25 · NCT04851119

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

  • Cleveland Clinic Taussig Cancer Institute, Cleveland
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-21 · NCT06774963

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

  • Research Site, Columbus
Renkami dalyviai1/2 fazė
Amžius nuo 18 iki 130 · Visoms lytims · Atnaujinta 2026-08-21 · NCT05797168

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

  • Ohio State University Comprehensive Cancer Center, Columbus
Renkami dalyviai2/3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-19 · NCT07001748

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

  • Normunity Investigational Site, Maumee
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-18 · NCT07182149

A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

  • Ohio State University Wexner Medical Center, Columbus
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-18 · NCT07470853

Effects of a Probiotic Intervention on the Gut and Vaginal Microbiome in Patients With Advanced or Recurrent Ovarian Cancer Undergoing Treatment With Platinum Chemotherapy

  • Ohio State University Comprehensive Cancer Center, Columbus
Renkami dalyviaiAnkstyvoji 1 fazė
Amžius 18 ir vyresni · Moterims · Atnaujinta 2026-08-17 · NCT07144826

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

  • The Ohio State University, Columbus
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-13 · NCT05985655

Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.